ClinicalTrials.gg
Active, not recruitingNCT06506903Updated Apr 21, 2026

Avalus Ultra Post-Approval Study (PAS)

An interventional study of Medtronic Avalus Ultra in Aortic Valve Disease, sponsored by Medtronic Cardiac Surgery. Active, not recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Medtronic Cardiac Surgery (part of Medtronic) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 47 studies in Aortic Valve Disease with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Aortic Valve Disease · United States.

Enrollment
16th of 31
190 · median 190
Started
2024
with 4 others
No phase
27 of 47
9 open now
Primary completion
2026-11
later than 10 of 22 live
Registered
41st of 47
by date

Among the 47 studies in Aortic Valve Disease with a site in United States, this one is the 16th largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2024, is one of 27 with no phase, reaches primary completion later than 10 of the 22 other live ones, and was the 41st registered.

Aortic Valve Disease

234 studies on the registry are indexed under Aortic Valve Disease; 70 are open to participants now.

Browse Aortic Valve Disease studies →

Open to participants now

12 of the 47 studies in Aortic Valve Disease with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Aortic Valve Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease.

Read the detailed description

A prospective, multi-center, single-arm, interventional, non-randomized, post-market study to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease. Approximately 150 subjects in the United States will be implanted and followed through one year post-procedure.

03

Conditions studied

  • Aortic Valve Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet the following criteria to be included in the study:

  1. Subject has moderate or greater aortic stenosis or regurgitation, and there is a clinical indication for replacement of their native or prosthetic aortic valve with a bioprosthesis, with or without concomitant procedures, which are limited to any of the following:

    • Atrial fibrillation (AF) ablation
    • Ascending aortic aneurysm or dissection repair or replacement, with or without circulatory arrest
    • Coronary artery bypass graft (CABG)
    • Surgical management of the left atrial appendage (LAA)
    • Patent foramen ovale (PFO) closure
    • Resection of a sub-aortic membrane not requiring myectomy
  2. Subject is geographically stable and willing to return to the implanting site for all follow-up visits
  3. Subject is of legal age to provide
  4. Subject has been adequately informed of risks and requirements of the study and is willing and able to provide informed consent for participation in the study

Exclusion criteria

Exclusion Criteria

Subjects who meet any of the following criteria will not be eligible for participation in the study:

  1. Subject has a pre-existing prosthetic valve or annuloplasty device in another position or requires replacement or repair of the mitral, pulmonary, or tricuspid valve
  2. Subject has had a previous implant and then explant of the Avalus Ultra aortic valve bioprosthesis within the Avalus Ultra Post-Approval Study
  3. Subject presents with active endocarditis, active myocarditis, or other systemic infection
  4. Subject has a known to contrast media that cannot be adequately premedicated
  5. Subject has a known hypersensitivity to platinum, iridium, or tantalum
  6. Subject has an anatomical abnormality that would increase surgical risk of morbidity or mortality, including:

    • Acute Type A aortic dissection
    • Ventricular aneurysm
    • Porcelain aorta
    • Hostile mediastinum
    • Hypertrophic obstructive cardiomyopathy
    • Documented pulmonary hypertension (systolic >60mmHg)
  7. Subject has a non-cardiac major or progressive disease with a of less than 1 year. These conditions include but are not limited to:

    • Class C liver disease
    • Terminal cancer
    • End-stage lung disease
  8. Subject has renal failure, defined by dialysis therapy or (GFR) \<30 mL/min/1.73 m2
  9. Subject has active or untreated hyperparathyroidism
  10. Subject is participating in another device or drug trial (not including registries)
  11. Subject is pregnant, lactating, or planning to become pregnant during the study period
  12. Subject has a documented history of substance (drug or alcohol) abuse
  13. Subject has greater than mild mitral valve regurgitation or greater than mild tricuspid valve regurgitation as assessed by echocardiography
  14. Subject has systolic (EF) \<20% as assessed by echocardiography
  15. Subject has Grade IV diastolic dysfunction
  16. Subject has documented bleeding diatheses
  17. Subject has had an acute preoperative neurological deficit or myocardial infarction and has not returned to baseline or stabilized ≥30 days prior to implant
  18. Subject requires emergency surgery
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    Avalus Ultra

    Avalus Ultra bioprosthesis: sizes 19mm, 21mm, 23mm, 25mm, 27mm, and 29mm

    Device: Medtronic Avalus Ultra

Interventions

  • DeviceMedtronic Avalus Ultra

    Surgical aortic valve replacement with the Medtronic Avalus Ultra bioprosthesis for management of aortic stenosis and regurgitation.

06

What researchers measure

Primary outcomes

  1. Time-related incidence of adverse events and death through 1 year post-procedure

    Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: thromboembolism, valve thrombosis, hemorrhage, paravalvular leak, endocarditis, structural valve deterioration, non-structural valve dysfunction, reintervention, death. This safety endpoint is descriptive, and no statistical hypothesis testing will be performed. The primary analysis of safety endpoint events will occur once all implanted participants have completed their 1 year post-procedure visit or exited the study.

    Time frame: 30 days and 1 year post-procedure

  2. Evaluation of Mean Pressure Gradient (mmHg) through 1 year post-procedure

    Mean pressure gradient is evaluated by transthoracic echocardiography technique as the average flow of blood through the aortic valve measured in millimeters of mercury. This effectiveness endpoint is descriptive, and will be summarized as with continuous data. No statistical hypothesis testing will be performed. The primary analysis of effectiveness endpoint events will occur once all implanted participants have completed their 1 year post-procedure visit or exited.

    Time frame: 30 days and 1 year post-procedure

  3. Evaluation of Effective Orifice Area (cm^2) through 1 year post-procedure

    Effective Orifice Area (EOA) is assessed by transthoracic echocardiography technique and is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve. This effectiveness endpoint is descriptive, and will be summarized as with continuous data. No statistical hypothesis testing will be performed. The primary analysis of effectiveness endpoint events will occur once all implanted participants have completed their 1 year post-procedure visit or exited.

    Time frame: 30 days and 1 year post-procedure

  4. Change in heart failure status based on NYHA functional classification from baseline through 1 year post-procedure

    The change of the New York Heart Association (NYHA) functional classification at 30 days and 1 year from baseline will be used to evaluate the change heart failure status. The primary analysis will occur once all implanted participants have completed their 1 year visit or exited; no statistical hypothesis testing will be performed. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.

    Time frame: 30 days and 1 year post-procedure

  5. Implanted valve size compared to pre-operative annulus dimensions on Multi-Detector Computed Tomography (MDCT)

    This effectiveness endpoint is descriptive, and no statistical hypothesis testing will be performed. The primary analysis of effectiveness endpoint events will occur once all implanted participants have completed their 1 year post-procedure visit or exited.

    Time frame: 1 year post-procedure

  6. Characterization of post-operative stent deformation on Multi-Detector Computed Tomography (MDCT)

    This effectiveness endpoint is descriptive, and no statistical hypothesis testing will be performed. The primary analysis of effectiveness endpoint events will occur once all implanted participants have completed their 1 year post-procedure visit or exited.

    Time frame: 1 year post-procedure

07

Study locations

15 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

Of 61 interventional studies with no phase under Aortic Valve Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 61. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 18, 2024
StartActual
Nov 20, 2024
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06506903
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
Nov 20, 2024
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Apr 21, 2026

Study contacts

Juan Crestanello, MD
principal investigator · Mayo Clinic
Bo Yang, MD, PhD
principal investigator · University of Michigan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion